Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightNo patients were lost in either group.Conclusion: In patients with early breast cancer, BCS was found to be disease-free and as safe as MRM surgeries for overall survival.
📌 3 Maddede Bu Makale
Özet
Objective: In the treatment of early-stage breast cancer, breast-conserving surgical treatment has been increasingly used. In our study, we investigated the survival efficacy in the long-term follow-up of breast-conserving surgical treatment in patients without axillary lymph node metastasis.Method: Thirty-nine patients without axillary lymph node metastasis who had undergone surgery for infiltrating ductal breast cancer between 2009 and 2018 were recordedin the research. Of these patients, 23 (58.9%) undergo MRM (modified radical mastectomy)and 16 (41.0%) undergo BCS (breast-conserving surgery). All of the patients who underwent BCS were given radiotherapy, and the patients with T2 and T3 tumors in two groups were given adjuvant chemotherapy and hormonotherapy according to receptor status. The patients were followed up by physical examination and imaging methods every three months in the first two years and then every six months.Results: All patients were followed up during the study (6 - 96 months). There was not variations between the 2 groups in terms of patient age, tumor localization, menopausal status, and the number of lymph nodes dissected. Local recurrence was detected in 1 (6.2%) patient who underwent BCS and was treated with a total mastectomy. In another patient, lung and liver metastases were detected in the 7th year. Infiltrative ductal carcinoma of the contralateral breast was detected in 3 (13%) patients who underwent MRM between 12-24 months. No patients were lost in either group.Conclusion: In patients with early breast cancer, BCS was found to be disease-free and as safe as MRM surgeries for overall survival.
Abstract
Amaç: Meme koruyucu cerrahi erken evre meme kanserinin tedavisinde gün geçtikçe daha fazla kullanılmaktadır. Çalışmamızda koltuk altı lenf nodu metastazı olmayan hastalarda meme koruyucu cerrahi tedavinin uzun süreli takibinde sağkalım etkinliğini araştırdık. Yöntemler: 2009-2018 yılları arasında aksiller lenf nodu metastazı olmayan ve infiltrative ductal meme kanseri ameliyatı geçiren 39 hasta çalışmaya dahil edildi. Bu hastaların 23’üne (%58.9) modifiye radikal mastektomi(MRM), 16’sına (%41.0) meme koruyucu cerrahi (MKC) uygulandı. MKC yapılan tüm hastalara radyoterapi, iki gruptaki T2 ve T3 tümörlü hastalara reseptör durumuna göre adjuvant kemoterapi ve hormonoterapi verildi. Hastalar ilk 2 yıl ve 3 ayda bir ardından 6 ayda bir fizik muayene ve görüntüleme yöntemleriyle takip edildi. Bulgular: Tüm hastalar çalışma süresince (6-96 ay) takip edildi. İki grup arasında hasta yaşı,tümör lokalizasyonu, menapoz durumu ve diseke edilen lenf nodu bakımından fark yoktu. MKC yapılan ve total mastektomi uygulanan 1(%6.2) hastada lokal nüks tesbit edildi. Diğer bir hastada 7.yılda akciğer ve karaciğer metastazı saptandı. 12-24 ay arasında MRM yapılan 3(%13) hastada memede infiltrative duktal karsinom saptandı. Her iki grupta da kaybedilen hasta olmadı. Sonuç: Erken evre meme kanseri olan hastalarda MKC’nin hastalıksız ve genel sağkalım açısından MRM ameliyatı kadar güvenli olduğu söylenilebilinir.